302 related articles for article (PubMed ID: 24384425)
1. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
[TBL] [Abstract][Full Text] [Related]
3. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
Laurent C; Bourgeois A; Mpoudi-Ngolé E; Ciaffi L; Kouanfack C; Mougnutou R; Nkoué N; Calmy A; Koulla-Shiro S; Delaporte E
AIDS Res Hum Retroviruses; 2008 Mar; 24(3):393-9. PubMed ID: 18327976
[TBL] [Abstract][Full Text] [Related]
5. Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting.
Kumarasamy N; Venkatesh KK; Devaleenol B; Saghayam S; Manohar D; Poongulali S; Yepthomi T; Ambrose P; Solomon S; Mayer KH
Int J Infect Dis; 2009 Nov; 13(6):e360-4. PubMed ID: 19328734
[TBL] [Abstract][Full Text] [Related]
6. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
[TBL] [Abstract][Full Text] [Related]
7. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
[TBL] [Abstract][Full Text] [Related]
8. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment.
Phe T; Thai S; Veng C; Sok S; Lynen L; van Griensven J
PLoS One; 2013; 8(3):e60206. PubMed ID: 23555926
[TBL] [Abstract][Full Text] [Related]
10. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies.
Moyle G; Sawyer W; Law M; Amin J; Hill A
Clin Ther; 2004 Jan; 26(1):92-7. PubMed ID: 14996521
[TBL] [Abstract][Full Text] [Related]
11. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
Siegfried NL; Van Deventer PJ; Mahomed FA; Rutherford GW
Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD004535. PubMed ID: 16625606
[TBL] [Abstract][Full Text] [Related]
12. ddI and d4T plus protease inhibitors.
GMHC Treat Issues; 1996 Nov; 10(11):8-9. PubMed ID: 11364012
[TBL] [Abstract][Full Text] [Related]
13. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
HIV Med; 2008 May; 9(5):317-21. PubMed ID: 18331562
[TBL] [Abstract][Full Text] [Related]
14. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
Bocket L; Yazdanpanah Y; Ajana F; Gerard Y; Viget N; Goffard A; Alcaraz I; Wattré P; Mouton Y
J Antimicrob Chemother; 2004 Jan; 53(1):89-94. PubMed ID: 14645320
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team.
Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; McKinney RE; Nichols S; Mitchell WG; Yogev R; Hutcheon N
Pediatrics; 1998 Feb; 101(2):214-20. PubMed ID: 9445494
[TBL] [Abstract][Full Text] [Related]
17. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
Phanuphak N; Ananworanich J; Teeratakulpisarn N; Jadwattanakul T; Kerr SJ; Chomchey N; Hongchookiat P; Mathajittiphun P; Pinyakorn S; Rungrojrat P; Praihirunyakit P; Gerschenson M; Phanuphak P; Valcour V; Kim JH; Shikuma C;
Antivir Ther; 2012; 17(8):1521-31. PubMed ID: 23220732
[TBL] [Abstract][Full Text] [Related]
18. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
20. Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Aurpibul L; Puthanakit T; Taejaroenkul S; Sirisanthana T; Sirisanthana V
Pediatr Infect Dis J; 2012 Apr; 31(4):384-8. PubMed ID: 22124211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]